Health Catalyst, Inc. (HCAT) has recently been assigned an Equal-Weight rating by analyst Stan Berenshteyn of Wells Fargo, effective March 18, 2026. This rating reflects a cautious outlook for investors in the company whose shares are currently trading at $1.17, suggesting limited near-term upside potential. With a price target of $1, the rating indicates that investors should neither aggressively buy nor sell the stock, as it grapples with ongoing market challenges.
Recent Price Action
In recent trading sessions, HCAT has experienced notable volatility, settling at $1.17, a slight decrease of $0.025 or 2.14%. This performance is particularly concerning given that it has plummeted 65.62% from its 52-week high, which amplifies investor skepticism. The annual volatility stands at 5.52% weekly and 5.20% monthly, underscoring a turbulent investment environment. With a market capitalization of approximately $84.26 million and trading volume near 726,119 against an average volume of about 800,000, the stock’s movements reflect a cautious market sentiment about the stock’s stability.
Short- and Long-Term Performance
A deeper dive into Health Catalyst’s performance reveals a sharp decline across various timeframes. Over the past 30 days, the stock has dropped by 7.53%, with a more severe quarterly decline of 27.54%. Looking further back, the annual performance is staggering, with HCAT’s shares losing roughly 59.82% of their value. This significant downturn aligns with broader market trends, as many healthcare stocks face pressure amid changing economic conditions and investor sentiment. Despite the recent high trading volume (averaging over 1 million shares in the past ten days), the stock has not been able to leverage that interest into positive performance outcomes.
Earnings / Financials
In its latest earnings report, Health Catalyst posted an actual earnings per share (EPS) of -$0.31586, far below the analyst estimate of $0.05. This substantial miss of approximately 732% raises concerns about the accuracy of forward guidance and the overall financial health of the company. Notably, in its prior report from August 7, 2025, HCAT had recorded an EPS of $0.04, which had impressed analysts slightly, as it exceeded the estimated $0.03. The significant divergence in recent earnings highlights increasing uncertainty and may impact future investor confidence.
Analyst / Consensus View
The prevailing analyst sentiment on Health Catalyst remains tepid. With seven ratings distributed among the analysts, only one has recommended a Buy, while six have maintained Hold ratings – no analysts rate the stock as a Sell. The average price target currently sits around $2.54, providing a glimmer of optimism against its current trading price. However, the low end of the price target spectrum is $1, aligning directly with Wells Fargo’s recent rating and illustrating the cautious outlook shared among analysts.
Stock Grading or Fundamental View
Health Catalyst’s Stocks Telegraph Grade stands at 37, reflecting a grade indicative of weak fundamentals. This score synthesizes various financial and market analytics, suggesting that the company is currently facing significant operational challenges. Investors are advised to stay informed, particularly given sector dynamics and the company’s financial performance track record.
Conclusion
Health Catalyst, Inc. presents a complex case for investors. With its significant downturn in stock value and a recent Equal-Weight rating from Wells Fargo, it may best suit cautious investors looking for potential value in a struggling name within the healthcare technology sector. However, the substantial earnings miss signals risks that potential investors must weigh carefully. In the current landscape, those considering an entry point should do so with the understanding that further volatility may lie ahead, alongside a need for improvements in financial performance and market sentiment.